Maxim Group initiated coverage of Atossa Genetics (NASDAQ:ATOS) with a “buy” rating and 12-month price target of $2. The stock closed at 33 cents on Jan. 25.Read More
William Blair launched coverage of Calithera Biosciences (NASDAQ:CALA) with an “outperform” rating. The stock closed at $16.05 on Oct. 5.Read More
Maxim Group slashed its price target for Stellar Biotechnologies (NASDAQ:SBOT) to $2 from $4, but maintained its “buy” rating, after the company reported fiscal second quarter results. The stock closed at $1.32 on May 9.Read More
BTIG initiated coverage of Cascadian Therapeutics (NASDAQ:CASC) with a “buy” rating and $13 price target. The stock closed at $3.92 On April 20.Read More
GeneNews (TSX:GEN) has launched BreastSentry, a new risk stratification test for breast cancer, via its Virginia-based clinical reference lab, Innovative Diagnostics Laboratory (IDL).Read More
GeneNews (TSX:GEN) has signed an agreement with a large, multi-specialty physician group in the American Midwest for use of its cancer diagnostic tests.Read More
Maxim Group downgraded Galena Biopharma (NASDAQ:GALE) to “hold” from “buy” and removed its price target after the departure of Galena CEO, Dr. Mark Schwartz. The stock was quoted at $1.11 at midday Feb. 2.Read More
Maxim Group raised its price target for Galena Biopharma (NASDAQ:GALE) to $4 from $1, saying the company has multiple programs moving forward, including NeuVax. The stock was quoted at $2.90 in afternoon trading on Dec. 2.Read More
Maxim Group reduced its price target for Stellar Biotechnologies (NASDAQ:SBOT) to $4 from $7, saying demand for the company’s keyhole limpet hemocyanin (KLH) is a slow climb. The stock was quoted at $2.59 at midday Dec 2.Read More
Maxim Group lowered its price target for Galena Biopharma (NASDAQ:GALE) to $1 from $2, citing a shift in the company’s pipeline focus. The stock closed at 46 cents on Tuesday.
At the end of June, an Independent Data Monitoring Committee stopped a Phase 3 trial of Galena’s NeuVax in early-stage breast cancer for futility.Read More
Maxim Group lowered its price target for Stellar Biotechnologies (NASDAQ:SBOT) to $7 from $17, citing market environment, catalysts related to clients for Stellar’s Keyhole Limpet Hemocyanin (KLH) protein, revisions to timelines for KLH revenues, and other related assumptions.
Shares of Stellar were quoted at $3.14 in afternoon trading on Monday.Read More
H.C. Wainwright analyst Swayampakula Ramakanth has assumed coverage of Celsion (NASDAQ:CLSN) with a “buy” rating and $3 price target. The stock closed at $1.30 on Monday.
Celsion has developed two cancer therapeutic platforms: LTSL for the delivery of chemotherapies and TheraPlas for the delivery of therapeutic DNA, RNA or proteins, both of which allow drugs to be delivered locally at high concentrations for greater therapeutic benefit and lower toxicity.Read More
Closely-held Soricimed Biopharma and collaborators plan to present four posters at the American Association of Cancer Research (AACR) annual meeting in New Orleans on April 16-20.
The presentations are based on preclinical and clinical research conducted on the company’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel.Read More